[Effect of adipose-derived mesenchymal stem cells and liraglutide on acute lung injury].
Zhonghua Jie He He Hu Xi Za Zhi · 2020
Last updated 2026-05-28In a study on mice with lung injury, combining human stem cells (AD-MSCs) with the drug liraglutide reduced lung damage and lowered the number of neutrophils in lung fluid compared to either treatment alone. Specifically, the combined treatment decreased neutrophils from about 65.63 ×10⁴/ml to 28.54 ×10⁴/ml at 2 days and from 51.67 ×10⁴/ml to 21.46 ×10⁴/ml at 7 days. The treatment also improved lung tissue health and increased a stem cell marker protein called Nanog.
AI summary of the abstract below.
| Journal | Zhonghua Jie He He Hu Xi Za Zhi, 2020 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.13 |
| NIH percentile | 9 |
| Molecules | liraglutide |
Abstract
To explore the protective effect of human adipose-derived mesenchymal stem cells (AD-MSCs) and liraglutide on lipopolysaccharide (LPS) -induced acute lung injury (ALI) . AD-MSCs were cultured and randomly divided into 3 groups: control group, LPS group (30 mg/L) , and LPS (30 mg/L) +liraglutide (10 nM) group. MTT assay was used to detect the proliferation of AD-MSCs at 6, 24, 48 and 72 h. Annexin V-FITC / PI double staining flow cytometry was used to detect the apoptosis of the cells. Western blot was used to detect the expression of apoptotic proteins cleaved caspase-3, Bax and Bcl-2 at 72 h . For the experiment, 60 male SPF BALB/c mice were randomly divided into 5 groups: control group, ALI group, ALI+AD-MSCs group, ALI+Liraglutide group, and ALI+AD-MSCs+Lraglutide group. The mice were sacrificed on day 2 and day 7 after LPS treatment. HE staining was used to examine the pathological changes of the lungs of mice, and the scores of lung injury were measured. The lung tissues of mice were examined by immunohistochemistry, and the expression of the marker protein Nanog of mesenchymal stem cells was observed. BALF was collected, and the number of BALF neutrophils was counted by Rayleigh Giemsa staining. The wet/dry specific gravity of mouse lung tissue was recorded. The apoptosis of AD-MSCs stimulated by LPS was significantly higher than that of the control group (0.05) , and the proliferation of AD-MSCs at 6, 24, 48 and 72 h was significantly lower than that of the control group (all 0.05) . The addition of Liraglutide reduced the apoptosis of AD-MSCs (0.05) , and promoted the proliferation of AD-MSC at 6, 24, 48 and 72 h. Compared with the control group, in the 2 d and 7 d model groups, the lung injury pathology of ALI group had lung injury, increased number of neutrophils in BALF (65.63±1.34 1.74±0.17, 51.67±1.35 1.55±0.13) ×10(4)/ml (all 0.05) , and increased W/D of lung tissues. The expression level of Nanog protein was low in the 7 d model group. Compared with the ALI group, in 2 d and 7 d model groups, the ALI+AD-MSCs group, the ALI+liraglutide group, and the ALI+AD-MSCs+liraglutide group showed reduced lung injury pathology, and the number of neutrophils was decreased, (37.04±1.23, 29.17±0.68) ×10(4) / ml (all 0.05) in the ALI+AD -MSCs group, (39.58±1.67, 35.42±0.25) ×10(4) / ml in the ALI+Liraglutide group (all 0.05) and (28.54±0.37, 21.46±0.89) ×10(4)/ml (all 0.05) in the ALI+AD-MSCs+Liraglutide group. Lung tissue W/D in the ALI+AD-MSCs group, ALI+Liraglutide group and ALI+AD-MSCs+Liraglutide group showed the same trend. Nanog protein expression increased in the 7 d model group. AD-MSCs play a protective role in acute lung injury in mice under the synergistic effect of liraglutide.
Verbatim abstract via PubMed 32894910 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.